Therefore, our cell-free PCR-based CNV ratio screening test of CCND1 and CDKN2A as well as EBV DNA load in NPC plasma may provide time-saving and valuable information to help effective monitoring NPC progression and recurrence. The gene discussed is CDKN2A; the disease is nasopharyngeal carcinoma.